Warning letter
www.dashpct.com: warning letter of Apr 24, 2024
FDA warning letter 679727 · Center for Drug Evaluation and Research | CDER
Key facts
| Reference number | 679727 |
|---|---|
| Company | www.dashpct.com |
| Subject | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet |
| Issue date | Apr 24, 2024 |
| Posted date | Apr 30, 2024 |
| Issuing office | Center for Drug Evaluation and Research | CDER |
| Product type | Drugs |
| CFR sections cited | 201.115(a), 201.5 |
| Country | 3 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: